BNET Industries
Ranbaxy Laboratories Ltd. is in the Pharma Industry
Latest News and Analysis
U.S. Authority Seeks Documents From India's Ranbaxy
MUMBAI (Reuters) - The U.S. Food and Drug Administration has filed a motion in a U.S. court seeking documents from Indian drugmaker Ranbaxy Laboratories Ltd RANB as part of an ongoing investigation, a Ranbaxy spokesman said on Sunday. Indian newspapers said U.S. authorities...
A Ranbaxy Bid Would Smell Like Desperation on Pfizer
Last last week, reports out of India suggested that Pfizer might make a hostile bid for generic-drug maker Ranbaxy Laboratories, which last week agreed to sell itself to Japan's Daiichi Sankyo for roughly $4 billion. Pfizer may or may not actually try to bust up the Daiichi-Ranbaxy...
Japanese Pharma Waves Its Charge Card
Japanese drugmakers are anxious to expand their presence in global pharma/biotech markets where they've long been largely shut out -- and the strong yen is making it cheaper for them to basically buy their way in. Interestingly enough, some of these deals are bypassing the U.S. altogether. ...
Additional Resources
Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
'First-to-File' Status Will Provide 180-Day Marketing Exclusivity Upon Final Approval PRINCETON, N.J., June 25 /PRNewswire/ -- Ranbaxy Laboratories Limited RLL, announced today that the company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total...
Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
Ranbaxy Will Market Generic Atorvastatin in the U.S. With 180 Days Exclusivity From Nov. 30, 2011 Agreement Also Resolves Caduet, Accupril Litigation in the US GURGAON, Harayana, India and PRINCETON, N.J., June 18 /PRNewswire/ -- Ranbaxy Laboratories Limited Ranbaxy, announced today that it has entered...
Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide
Ranbaxy to Receive License in U.S. on November 30, 2011; Pfizer to Host Conference Call Today at 9 a.m. EDT NEW YORK -- Pfizer Inc announced today that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its...
Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
TOKYO and NEW DELHI, India, June 11 /PRNewswire/ -- Daiichi Sankyo Company, Limited ("Daiichi Sankyo"), one of the largest pharmaceutical companies in Japan, and Ranbaxy Laboratories Limited (NSE/BSE: Ranbaxy/500359) ("Ranbaxy"), among the top 10 generic companies in the world and India's largest pharmaceutical company, announced on June 11...
Japan's Daiichi Sankyo in 4.6 bin dlr takeover of India's Ranbaxy
NEW DELHI AFP — Japanese pharmaceutical firm Daiichi Sankyo said Wednesday it would buy control of top Indian generics firm Ranbaxy for up to 4.6 billion dollars, entering the fast-expanding copycat drugs market. Daiichi Sankyo, Japan's third-largest drugmaker, said it would purchase the 35 percent stake held by...
Unleashing Africa's potential
One of last year's most enthralling sessions at the 2007 World Economic Forum on Africa was entitled 'Unleashing Opportunity: A Blueprint for Africa's Growth'. The debate heard the president of South Africa, Thabo Mbeki, call on investors to tell government leaders about specific problems they encounter when doing business in...
U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent
NEW YORK -- Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of the claims of Pfizer's '893 basic patent for Lipitor. The Patent Office had conducted a re-examination of the '893 patent in response...
Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
Ohm Laboratories to Market in OTC Private Label Market PRINCETON, N.J., April 25 /PRNewswire/ -- Ohm Laboratories Inc Ohm, a wholly owned subsidiary of Ranbaxy Laboratories Limited RLL, announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market...
Shire galvanised by renewed bid speculation
MARKET REPORT Renewed bid talk took the pharmaceutical group Shire to an intra- day high of 956p yesterday. Market speculation suggested AstraZeneca was again mulling a bid for the company. An earlier UBS note, which said "AstraZeneca can pay up to 1,425p [a share]...
Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
Companies Also Sign Manufacturing and Distribution Agreement GURGAON, India and PRINCETON, N.J., April 15 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. RPI, a wholly owned subsidiary of Ranbaxy Laboratories Limited RLL, announced today that it has reached several agreements with AstraZeneca. Two of these agreements concern Esomeprazole magnesium...
Indian billionaires to buy City's oldest stockbrokers
Hichens, Harrison & Co, the City of London's oldest active stockbroker, is in talks to be taken over by an Indian financial group backed by two billionaire brothers in a deal worth almost 50m. Hichens, which has been operating in London since 1803, yesterday confirmed it was...
Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent, Decision Prevents Launch of Generic Product by Ranbaxy until 2010
NEW YORK -- Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer's enantiomer patent could not block generic manufacturer Ranbaxy Laboratories Limited from obtaining approval for a competitor product to Lipitor. The appellate court issued an order...
Ranbaxy Laboratories
Ranbaxy Laboratories has received tentative approval from the Food and Drug Administration for esomeprazole magnesium delayed-release capsules, 20 mg and 40 mg. This is the genetic version of AstraZeneca's drug, Nexium. Nexium is indicated for the short-term treatment four to eight weeks in the healing and symptomatic resolution...
FTC accuses Cephalon over Provigil in patent case
The Federal Trade Commission filed a lawsuit yesterday against Cephalon Inc. over deals it struck with four makers of generic drugs that had challenged the patent on Cephalon's biggest drug, Provigil. The agreements, which the FTC said were worth more than $200 million, would prevent four companies - Teva Pharmaceutical...
USIBC Launches Investing in America: The Indian Story, February 12, 2008
To: FOREIGN EDITORS Contact: Anku Nath of the U.S.-India Business Council, +1-202-463-5886, anath@uschamber.com WASHINGTON, Feb. 12 /PRNewswire-USNewswire/ -- The U.S.-IndiaBusiness Council USIBC, in partnership with the Federation ofIndian Chambers of Commerce and Industry FICCI, will launch theInvesting in America: The Indian Story initiative in Chicago,Illinois on February 19th at...
Drug Makers Approved To Sell Zyrtec Knockoffs
Nine generic drug makers including three in New Jersey were approved by the U.S. Food and Drug Administration last week to sell knockoffs of Zyrtec, Pflzer's prescription allergy fighter, as over-the-counter medicines, according to the FDA. Manufacturers including Par Pharmaceutical Companies, Inc. of Woodcliff Lake, India's Ranbaxy Laboratories Ltd....
Young Global Leaders Advance Global Dignity on a 3-Day Tour Covering Two Continents
The Movement to promote Global Dignity GDgot another boost this month when founders His Royal Highness Crown PrinceHaakon Magnus of Norway; Pekka Himanen, Professor of Philosophy, Universityof Art and Design Helsinki, and silver rights leader and Operation HOPE CEOJohn Hope Bryant, also fellow Young Global Leaders of the World EconomicForum,...
- Next »
- page 1 of 12
- « Previous
Sort byClose
Ranbaxy Laboratories Ltd. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412Brought to you by IBMSponsored Resources
